Pro-Salosa n. 66-33.

Approved for use through 07-31/2003 - OMB 051-0031

U. S. Pateni and Trademark Office, U. S. DEPARTMENT OF COMMERCE

Urdor the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unterest contains a valid of corred number.

Complete if Known Substitute for form 1449A/B/PTO 09/902,705-Conf. #8314 Application Number INFORMATION DISCLOSURE July 12, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Daniel P. Bednarik Art Unit 1652 (Use as many sheets as necessary) Examiner Name Steadman, D. RAMIREZ of 2 PF138P1C1 Sheet Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Find Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages. Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
35	AA	4,749,570	06-07-1988	POZNANKY et al.		
OR	AB	5,108,921	04-28-1992	LOW et al.		
DR.	AC	US 09/912,292		ROSEN et al.	Pages 1-75 (pages 1 and 2 partially redacted); portion of Table 2; and SEQ ID NO:23842	
	AD	5,082,670	01-21-1992	GAGE et al.		
DIL	AE	5,118,601	06-02-1992	GRUBER et al.		
DR	AF	RE 34,387	09-21-1993	HOLMES et al.		

FOREIGN PATENT DOCUMENTS							
E>aminer Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁵		
35	AG	WO-94/17183	08-04-1994	BERGMANN et al.	3 0		
200	AH	WO-97/42320	11-13-1997	PAULAKIS et al.	2 . 1		

"E «AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw time through citation if all conformance considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (options)." See Kings Codes of USPTO Patent Documents at xxiv xiggio gay or MPEP 901 04. "Enter Office hall issued the document, by the wo-letter code (WIPO Standard's 13). "Xigging and office the conformance of the patent document which of the patent document which of the patent document that the Emptor xing storeoche the serial number of the patent document." Nan of of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a cneck mark here if English language Translation is stached."

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials						
DR	AI	OLSEN and MILMAN, "Chinese hamster hypoxanthine-guanine phosphoribosyltransferase," J.Biol Chem., 249(13):4030-4037 (1974).	Γ			
DR.	AJ	Biochemistry by A.L. Lehninger, Published by Worth Publishers, Inc., 70 Fifth Ave., NY, NY 10011, PP. 109-122.				
	AK	HARPER et at., "Review of Physiological Chemistry, 16th Edition," Lange Medical Publications, Los Altos, PP 496-498.	ø			
	AL	BROWN, "Gene Therepy 'Oversold' by Researchers, Journalists;" The Washington Post,	Ž.			
M	АМ	1990 Sigma Chemical Company Catalog, (Published by Sigma Chemical Company, P.O. Box 14508, St. Louis, Missouri), Page 1100.				
DR	AN	OLARU et al., Revue Roumaine De Biochimie, Volume 18, Number 2, pages 131-137 (full document) (1981).				
OR	AO	DAVIDSON et al., Purine and Pyrimidine Metabolism in Man VII, Part B (Published by Plenum Press, New York, New York) pages 1-5-108, (1991).				
DR.	AP	MILLER et al. "A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT." Proc. Natl. Acad. Sci. USA, Aug. 80(15):4709-4713, (1983).				
OR_	AQ	PALELLA et at., "Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector," Gene, 80(1):137-144, (1989).				
200	AR	ANDERSON W.F., "Prospects for human gene therapy," Science, 226:401-409 (1984).	1-			

Date Considered

Examiner



PTO:SB/08a b (09-03)
Approved for use through 07/31/2003 OMB 6651-0031
U.S. Patent and Trademark, Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 09/902,705-Conf. #8314 Application Number INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT First Named Inventor Daniel P. Bednarik 1652 Art Unit (Use as many sheets as necessary) Studeman, D. RAMIREZ Examirier Name PF138P1C1 2 of 2 Sheet Attorney Docket Number

r	-	ĀS .	CHANCAC and All MAN 50 addison.			
احا	- '	AS.	GHANGAS and MILMAN, "Radioimmune determination of hypoxanthine			
			phophoribosyltransferase crossreacting material in crythrocytes of Lesch-Nyhan patients,"			
12	\dashv	Proc. Natl. Acad. Sci. USA, 72(10):4147-4150, (1975).				
AT MELTON et al., "Structure, expression, and mutation of the hypoxanthine						
12	4	phosphoribosyltransferase gene," Proc. Natl. Acad. Sci. USA, 81:2147-2151 (1984).				
0	100	AU JOLLY et al., "Isolation and charcterization of a full-length expressible cDNA for hun				
_		hypoxanthine phosphoribosyl transferase," Proc. Natl. Acad. Sci. USA, 80:477-481,				
12W	AV PATEL et al., "Organization of the HPRT gene and related sequences in the hum Somatic Cell and Molecular Genetics, 10/5):483-493 (1984)					
Contract Contract Contract Contract, Total, 100 100 (100 1)						
SCULLEY et al., "A review of the molecular basis of the hypoxanthine-guani phosphoribosyltransferase (HPRT) deficiency," Hm. Genet., 90:195-207. (19						
		A 3/				
		AX	YIP and BALIS, "Polyamine-polyphosphate complexes as enzyme inhibitors," Biochemistry,			
	19:1849-1856 (1980).					
0	(\Box)	AY	YUAN et al., "Steady-state kinetics of the schistosomal hypoxanthine-guanine			
		ΑZ	phosphoribosyltransferase," Biochemistry, 31:806-810, (1992)			
m	2'	AZ.	WU and MELTON, "Production of a model for Lesch-Nyhan syndrome in hypoxanthine			
	2	BA	phosphoribosyltransferase-deficient mice," Nature Genetics, 3:235-240, (1993).			
[25)		BB	Genbank Entry Accession No T00169 (1992). Genbank Entry Accession No T00115 (1992).			
├ ─-├-		BC	Genbark Entry Accession no 100113 (1992).			
⊢⊹		BD BD	Genbank Entry Accession No T23947 (1994).			
\vdash		BE	Genbank Entry Accession No. T24112 (1994)			
⊢⊹		BF	Genbank Entry Accession No T24119 (1994).			
╌┼		BG	Genbank Entry Accession No. T00696 (1992) Genbank Entry Accession No. T11051 (1993).			
-		BH	Genbalik Entry Accession No. 1 (1953)			
⊢⊢		BI	Genbank Entry Accession No. T02687 (1993).			
H		BJ	Genbank Entry Accession No. T00217 (1992)			
\vdash		BK BK	Genbank Entry Accession No 120115 (1992).			
\vdash		BL BL	Genbank Entry Accession No. 247172 (1995).			
┢		BM :	Genbank Entry Accession No. L25928 (1993). Genbank Entry Accession No. L26978 (1995).			
		BN	Genbank Entry Accession No. A20700 (1994)			
⊢⊣		BO BO	Genbank Entry Accession No. A20700 (1994) Genbank Entry Accession No. A20702 (1994).			
		BP	Genbank Entry Accession No. 106859 (1994).			
3		BQ				
			Genbank Entry Accession No L25927 (1993).			
	الم	BR	HASSETT et al., "Characterization of cDNA clones encoding rabbit and human serum			
10%	paraoxonase: the mature protein retains its signal sequence," Biochemistry, 30(42):10141-					
<u> </u>	٦,	00	10149, (1991)			
 ~~	BS ADKINS et al., "Molecular basis for the polymorphic forms of human serum					
10	4	paraoxonase/arylesterase: glutamine or arginine at positon 191, for the respective A or B				
-	0 1	вт	allozymes," Am. J. Hum. Genet., 52:598-608, (1993).			
LZ7	PT JOHNSON et al., Biological Abstracts, 69(7):4678, (1980).					

'EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant

'Applicant's unique citation designation number (optional) *Applicant is to place a check mark here if English language Translation is attached

Examiner X /	Date		
Signature Della Xa Muez	00.0	111	110 1125
Signature Comment	Considered		12/02
		$\overline{}$	